



NUCLEA
BIOTECHNOLOGIES

PRESS RELEASE

For Immediate Release:
March 1, 2011

Contact: Conor Yunits
508.728.2964 cell
617.695.0369 office

NUCLEA BIOTECHNOLOGIES RECEIVES U.S. PATENT 7,897,354 FOR KINASE PEPTIDES AND ANTIBODIES

Pittsfield – Worcester, MA -- Biomarker pioneer Nuclea Biotechnologies, Inc. today announced the United States Patent and Trademark Office has issued patent number 7,897,354 covering kinase peptides and antibodies.

The invention relates to novel antibodies and methods of raising them using specific kinase peptides. Kinase antibodies play a key role in the early detection of breast cancer, especially in difficult-to-diagnose patients, and enhance the accuracy of mammographic studies in those populations. They are also useful for determining or monitoring the efficacy of treatment.

This is the eighth patent for Nuclea, which discovers and develops biomarkers and diagnostic assays that can help predict the stage or aggressiveness of certain cancers, as well as which treatments will be effective for certain patients, depending on their genetic makeup.

“This is another major step forward for Nuclea and the future of personalized medicine,” said Patrick J. Muraca, president & CEO of Nuclea Biotechnologies, Inc. “Our continued research in this field will lead to more comprehensive detection and more effective treatment of breast cancer and other deadly diseases.”

Nuclea Biotechnologies, Inc. is headquartered in Pittsfield, Massachusetts with additional operations in Worcester, Massachusetts. Nuclea has three lines of business, each of which is operated by a separate wholly-owned subsidiary: Nuclea Diagnostic Laboratories (“NDL”) which has developed and is commercializing eleven unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer; Nuclea Biomarkers (“NBM”) which performs research leading to novel molecular oncology therapeutics and diagnostics for the pharmaceutical and biotechnology industries and performs services by analyzing and testing the efficacy and validating other indications of existing therapeutics utilizing a highly characterized and consented patient database; and Nuclea Biotherapeutics (“NBT”) which has developed several therapeutics now in animal trials.